CD133 suppresses neuroblastoma cell differentiation via signal pathway modification

被引:0
作者
H Takenobu
O Shimozato
T Nakamura
H Ochiai
Y Yamaguchi
M Ohira
A Nakagawara
T Kamijo
机构
[1] Division of Biochemistry and Molecular Carcinogenesis,Department of Pediatrics
[2] Chiba Cancer Center Research Institute,Division of Biochemistry and Innovative Cancer Therapeutics
[3] Laboratory of Anti-tumor Research,undefined
[4] Chiba Cancer Center Research Institute,undefined
[5] Core Facility for Therapeutic Vectors,undefined
[6] The Institute of Medical Science,undefined
[7] The University of Tokyo,undefined
[8] Graduate School of Medicine,undefined
[9] Chiba University,undefined
[10] Laboratory of Cancer Genomics,undefined
[11] Chiba Cancer Center Research Institute,undefined
[12] Chiba Cancer Center Research Institute,undefined
来源
Oncogene | 2011年 / 30卷
关键词
CD133; neuroblastoma; differentiation; RET; p38MAPK; PI3K/Akt;
D O I
暂无
中图分类号
学科分类号
摘要
CD133 (prominin-1) is a transmembrane glycoprotein expressed on the surface of normal and cancer stem cells (tumor-initiating cells), progenitor cells, rod photoreceptor cells and a variety of epithelial cells. Although CD133 is widely used as a marker of various somatic and putative cancer stem cells, its contribution to the fundamental properties of cancer cells, such as tumorigenesis and differentiation, remains to be elucidated. In the present report, we found that CD133 was expressed in several neuroblastoma (NB) cell lines/tumor samples. Intriguingly, CD133 repressed NB cell differentiation, for example neurite extension and the expression of differentiation marker proteins, and was decreased by several differentiation stimuli, but accelerated cell proliferation, anchorage-independent colony formation and in vivo tumor formation of NB cells. NB cell line and primary tumor-sphere experiments indicated that the molecular mechanism of CD133-related differentiation suppression in NB was in part dependent on neurotrophic receptor RET tyrosine kinase regulation. RET transcription was suppressed by CD133 in NB cells and glial cell line-derived neurotrophic factor treatment failed to induce RET in CD133-expressing cells; RET overexpression rescued CD133-related inhibition of neurite elongation. Of note, CD133-related NB cell differentiation and RET repression were mainly dependent on p38MAPK and PI3K/Akt pathways. Furthermore, CD133 has a function in growth and RET expression in NB cell line- and primary tumor cell-derived tumor spheres. To the best of our knowledge, this is the first report of the function of CD133 in cancer cells and our findings may be applied to improve differentiation induction therapy for NB patients.
引用
收藏
页码:97 / 105
页数:8
相关论文
共 211 条
[1]  
Aoyama M(2005)LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma Cancer Res 65 4587-4597
[2]  
Ozaki T(2009)The stem cell marker CD133 (prominin-1) is phosphorylated on cytoplasmic tyrosine-828 and tyrosine-852 by Src and Fyn tyrosine kinases Biochemistry 48 3998-4007
[3]  
Inuzuka H(2005)Prospective identification of tumorigenic prostate cancer stem cells Cancer Res 65 10946-10951
[4]  
Tomotsune D(2000)The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions J Biol Chem 275 5512-5520
[5]  
Hirato J(2001)Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein Biochem Biophys Res Commun 285 939-944
[6]  
Okamoto Y(2004)Dok-6, a Novel p62 Dok family member, promotes Ret-mediated neurite outgrowth J Biol Chem 279 42072-42081
[7]  
Boivin D(1995)Expression of the RET oncogene induces differentiation of SK-N-BE neuroblastoma cells Cell Growth Differ 6 1387-1394
[8]  
Labbé D(2001)RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons Development 128 3963-3974
[9]  
Fontaine N(2000)Development of cranial parasympathetic ganglia requires sequential actions of GDNF and neurturin Development 127 4877-4889
[10]  
Lamy S(2006)Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors Cancer Res 66 7445-7452